Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
UBS
Boehringer Ingelheim
Mallinckrodt
Deloitte
Cantor Fitzgerald
QuintilesIMS
US Army
Farmers Insurance

Generated: June 24, 2018

DrugPatentWatch Database Preview

OMNISCAN Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Omniscan, and what generic alternatives are available?

Omniscan is a drug marketed by Ge Healthcare and is included in two NDAs.

The generic ingredient in OMNISCAN is gadodiamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gadodiamide profile page.
Drug patent expirations by year for OMNISCAN
Pharmacology for OMNISCAN
Synonyms for OMNISCAN
[N,N-bis(2-{[(carboxy-kappaO)methyl][2-(methylamino)-2-(oxo-kappaO)ethyl]amino-kappaN}ethyl)glycinato(3-)-kappa(2)N,O]gadolinium
[N,N-bis(2-{[(carboxy-kappaO)methyl][2-(methylamino)-2-(oxo-kappaO)ethyl]amino-kappaN}ethyl)glycinato(3-)-kappa(2)N,O]gadolinium--water (1/1)
0RPE15QPL0
122795-43-1
131410-48-5
131410-48-5 (parent)
2-[bis[2-[[2-(methylamino)-2-oxidanylidene-ethyl]-(2-oxidanidyl-2-oxidanylidene-ethyl)amino]ethyl]amino]ethanoate; gadolinium(3+)
2-[bis[2-[[2-(methylamino)-2-oxoethyl]-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(3+)
2-[bis[2-[[2-(methylamino)-2-oxoethyl]-(2-oxido-2-oxoethyl)amino]ethyl]amino]acetate; gadolinium(3+); hydrate
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxo-ethyl]amino]ethyl]amino]acetate; gadolinium(3+); hydrate
2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate; gadolinium(3+)
2220AH
3688AH
84F6U3J2R6
A806259
AB0108221
AB01568258_01
AC-925
AC1L1TUZ
AC1L4BCU
AKOS015900642
AKOS015967052
AN-15426
AN-32849
APAC 826031
BC220477
C13106
C16H26GdN5O8.xH2O
C16H26N5O8.Gd
C16H26N5O8.Gd.H2O
CAS-122795-43-1
CHEBI:31642
CHEBI:37333
CS-2254
CS-3925
CTK8E8484
D01645
D03EEH
D04284
DB00225
DSSTox_CID_28573
DSSTox_GSID_48647
DSSTox_RID_82845
DTXSID9048647
DV 7572
Gadodiamida
Gadodiamida [INN-Spanish]
gadodiamide
Gadodiamide (hydrate)
Gadodiamide (USP/INN)
Gadodiamide [USAN:USP]
Gadodiamide [USP]
Gadodiamide anhydrous
Gadodiamide hydrate
Gadodiamide hydrate (JAN)
Gadodiamide(hydrate)
Gadodiamidum
Gadodiamidum [INN-Latin]
gadolinium [bis(2-{(carboxylatomethyl)[2-(methylamino)-2-oxoethyl]amino}ethyl)amino]acetate
gadolinium [bis(2-{(carboxylatomethyl)[2-(methylamino)-2-oxoethyl]amino}ethyl)amino]acetate--water (1/1)
gadolinium 5,8-bis(carboxylatomethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oate
gadolinium 5,8-bis(carboxylatomethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oate hydrate
Gadolinium-DTPA-BMA
Gadolinium, (5,8-bis((carboxy-kappaO)methyl)-11-(2-(methylamino)-2-(oxo-kappaO)ethyl)-3-(oxo-kappaO)-2,5,8,11-tetraazatridecan-13-oato(3-)-kappaN5,kappaN8,kappaN11,kappaO13)-
Gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)- 3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate
Gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate
gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)[(methylcarbamoyl)methyl]amino]ethyl})amino]acetate hydrate
GADOLINIUM(3+) ION 2-[BIS({2-[(CARBOXYLATOMETHYL)[(METHYLCARBAMOYL)METHYL]AMINO]ETHYL})AMINO]ACETATE HYDRATE
gadolinium(III) 5,8-bis(carboxylatomethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oate
Gd DTPA-BMA
GDDTPA-BMA
HSDB 7547
HY-B0266
HY-B0787
J-004857
KS-00001F70
LS-186651
LS-70966
MOLI001033
NCGC00182547-01
NCGC00182547-02
NCGC00184996-01
Omniscan (TN)
PL044407
RT-013070
S-041
s1751
SC-19852
SCHEMBL3175139
SCHEMBL73031
ST51053862
TL8000744
Tox21_112999
Tox21_113000
Tox21_113000_1
UNII-0RPE15QPL0
UNII-84F6U3J2R6
VA10992

US Patents and Regulatory Information for OMNISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-001 Sep 5, 2007 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-002 Sep 5, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for OMNISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 022066-001 Sep 5, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Ge Healthcare OMNISCAN gadodiamide INJECTABLE;INJECTION 020123-001 Jan 8, 1993 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Cipla
Dow
Moodys
Chubb
Deloitte
Baxter
Healthtrust
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.